Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Cimzia's setback paves way for other TNF inhibitors in Crohn's disease

Nature Biotechnology volume 25, pages 487–488 (2007)Cite this article

Abstract

The drugmaker's management consistently understated the problems it faced from FDA.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Dublin

    Cormac Sheridan

Authors
  1. Cormac Sheridan
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

Related links in Nature Research

Billion dollar babies—biotech drugs as blockbusters

First-in-class biologic to enter rheumatoid arthritis fray

Rheumatoid arthritis market

Web links

UCB

Abbott

Centocor

Xencor

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sheridan, C. Cimzia's setback paves way for other TNF inhibitors in Crohn's disease. Nat Biotechnol 25, 487–488 (2007). https://doi.org/10.1038/nbt0507-487

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0507-487

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing